Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?
Jun 24, 2026
Proactive Equities Team
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.